Eli Lilly (NYSE:LLY) announced today that it committed an additional $4.5 billion investment across certain Indiana manufacturing sites. The company’s commitment extends to two of its three locations in Lebanon, Indiana. It brings its total Indiana capital expansion commitments since 2020 to more than $21 billion. This marks the latest investment across the U.S., with…
Lilly to build $3.5B injectable medicine, device manufacturing plant in Pennsylvania
Eli Lilly (NYSE:LLY) today announced plans to invest more than $3.5 billion to build a new manufacturing plant in Pennsylvania. The site, in Lehigh Valley, will serve as the company’s newest injectable medicine and device manufacturing facility. Indianapolis-based Lilly plans to produce next-generation weight-loss therapies there, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon…
Eli Lilly to build new $6B API manufacturing facility in Alabama
Eli Lilly (NYSE:LLY) announced that it plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The next-generation synthetic medicine active pharmaceutical ingredient (API) facility marks the third of four new U.S. sites. It follows the new facilities announced in Virginia and Texas. Eli Lilly plans for the plant to produce small-molecule…
Lilly plans new oral medicine manufacturing plant in Europe
Eli Lilly (NYSE:LLY) announced today that it plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands. Located within the Leiden Bio Science Park, the new project aims to expand Lilly’s capacity to produce oral medicines. The company also hopes to strengthen its global supply chain with the new plant. Indianapolis-based Lilly…
Eli Lilly invests more than $1.2B in Puerto Rico plant
Eli Lilly (NYSE:LLY) announced today that it plans to invest more than $1.2 billion to expand and modernize a manufacturing site in Puerto Rico. The company plans to integrate advanced technologies and expand production capacity within the existing campus at its Lilly del Caribe plant in Carolina, Puerto Rico. It hopes to support its growing…
Lilly to build new $6.5B API manufacturing plant in Texas
Eli Lilly (NYSE:LLY) announced today that it plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. The planned next-generation synthetic medicine active pharmaceutical product (API) facility marks the second of four new sites Lilly plans to announce this year. It follows the announcement of a $5 billion manufacturing facility…
Eli Lilly to build $5B manufacturing plant in Virginia
Eli Lilly (NYSE:LLY) announced today that it plans to build a $5 billion manufacturing facility in Goochland County, Virginia. The new site, just west of Richmond, will be the company’s first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for Lilly’s emerging bioconjugate platform and monocloncal antibody portfolio, according to a news…
Eli Lilly to more than double U.S. manufacturing investment
Eli Lilly (NYSE:LLY) announced today that it plans to boost domestic pharmaceutical production with four new U.S. manufacturing sites. The company’s investment in capital expansion across therapeutic areas in the U.S. now totals more than $50 billion since 2020. Indianopolis-based Eli Lilly says three of the future U.S. sites will focus on manufacturing active pharmaceutical…
Purdue, Eli Lilly, Merck form new pharma manufacturing consortium
Purdue University, Eli Lilly and Co., and Merck & Co. have launched the Young Institute Pharmaceutical Manufacturing Consortium, a collaborative effort to pioneer advances in making medicines. Operating within Purdue’s William D. and Sherry L. Young Institute for Advanced Manufacturing of Pharmaceuticals, consortium partners will focus on advancing pharmaceutical manufacturing, according to a Jan. 17 news…
Lilly gets nod to market locally manufactured insulin in Egypt
Eli Lilly (NYSE:LLY) announced today that the Egyptian Drug Authority approved insulin glargine manufactured in partnership with Eva Pharma. The companies launched their collaboration in 2022 to deliver a sustainable supply of high-quality, affordable human and analog insulin. It wants to bring insulin to at least 1 million people annually living with diabetes in low- to…